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Background: The high cost of CD4 count estimation in resource-limited countries is a major challenge in initiating
patients on highly active antiretroviral therapy (HAART). Therefore, assessment of inexpensive and simple laboratory
diagnostic marker is mandatory to diagnose immuno-suppression.
Objective: To evaluate utility of total lymphocyte count (TLC) as surrogate marker for CD4 count in HIV-infected
patients.
Materials and Methods: In this cross sectional study, 400 ART-naive HIV-positive patients enrolled in Gondar
University Hospital, from March 2011 to May 2011, were tested for CD4 count & TLC. The cutoffs were determined
as: 200 cells/μL for CD4 count and 1200 cells/μL for TLC by using BD FACS count and CELL DYN 1800 Flow
Cytometrys respectively. Spearman correlation between TLC and CD4 cell count were assessed. Sensitivity,
specificity, positive and negative predictive values for different age a group, TLC ≤1200 was computed for CD4
count ≤200 cells/cu.mm.
Results: Among 400 ART naive HIV infected patients, 278 (69.5%) were females. The mean age of the study
participants was 33.7. TLC and CD4 count were positively correlated (r = 0.33, p = 0.001). A TLC of ≤1200 cells/m m3
was found to have a sensitivity (32.86%), specificity (95.33%), PPV (79.7%), and NPV (71.9%) for predicting a CD4
count of <200 cells/mm3.
Conclusion: This study showed that low sensitivity and specificity of TLC as a surrogate measure for CD4 count.
Moreover, CD4 cell counts of< 200 cells/mm3 were found in 96 cases (24%) with TLCs of ≤1200 cells/mm3. Thus, 1
in 4 individuals would have been deprived of needed treatment. Therefore, we recommend keep on expansion of
access to CD4 counter.
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The saddle of HIV in resource-limited countries is wide
and a large proportion of HIV patients rely on accessing
health care services in rural and underserved areas that
do not have the capacity or capability to determine CD4
cell counts. Viral loads and CD4 counts require highly
skilled laboratory personnel and costly maintenance of
complicated equipment [1]. However, Health providers
in resource-constrained settings may not have access to* Correspondence: get29f@gmail.com
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distribution, and reproduction in any mediumthis laboratory measurement or its cost may be prohibi-
tive, resulting in the need for an alternative, surrogate
marker. Given the decreasing costs and increased avail-
ability of antiretroviral therapy (ART) in the developing
world, this is an issue of critical and increasing import-
ance [2]. World Health Organization guidelines advocate
the use of TLC as a surrogate marker for CD4 cell count
[3]. Moreover a number of previous studies indicate that
the total lymphocyte count (TLC) may be useful as a
surrogate marker of immune status in certain settings
[4]. However, controversy regarding the utility of the
TLC remains.entral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Table 1 Mean and range of CD4 count and TLC among
HIV infected patients at Gondar University Hospital, 2011
Marker Mean Median SE Mean SD Range
CD4 count cells/μL 288 252.5 9.512 190.24 6-1193
TLC cells/μL 2120 1850 57.42 1148.47 350-8480
Abbreviation: CD4, T-lymphocyte CD4 positive; TLC, Total lymphocyte count;
SD, standard deviation; HIV, Human immunodeficiency virus.
Table 2 Mean of CD4 count and TLC between both sexes









male 122 249.26 P= 0.45 1982.27 P = 0.60
female 278 306.15 2183.60
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concluded a decline in TLC was strongly correlated with a
decline in CD4 count, however there were some discrep-
ancies [5]. On the other hand, there is a report which
showed due to low sensitivity and specificity, TLC< 1200
cells/mm3 to envisage absolute CD4 count< 200 cells/
mm3 was not optimal for identifying patients requiring
HAART [6,7]. This showed that the data regarding this
issue is still mixed. Moreover, there is also limited infor-
mation on the relationship between CD4 cell counts and
total lymphocyte count in resource-limited settings. In
addition, most of the previous studies in different settings
were used small sample sizes in HIV- naïve patients. This
study was initiated to ascertain the reliability of total
lymphocyte count as a substitute for CD4 cell count using
relatively large sample size.
Methods
This cross sectional study was conducted, March 2011
to May 2011 in Gondar University Hospital HIV clinic.
This clinic provides care for patients referred from a
wide range of primary healthcare facilities in Gondar
Town. Using systematic random sampling technique
study subjects were selected. The study sample includes
HIV-infected adults, 18 years or older and pre-ART HIV
positives patients. Study exclusion criteria were anti-
retroviral therapy and tuberculosis, endocarditis and
acute viral infection suspected patients which could
affects WBC.
Blood samples were taken from the subjects and
hematological indices, such as white blood cell count,
and WBC differential count, were determined by auto-
mated blood analyzer (CELL-DYN 1800, Abbott Labora-
tories Diagnostics Division, USA. The CD4 T
lymphocytes count was determined using the Becton
Dickinson (BD) FASCount system (Becton, Dickinson).
The BD FASCount system used flow cytometry for the
quantification of the CD4 T Lymphocytes. TLC is easily
obtained from the routine complete blood count (CBC)
with differential through multiplication of lymphocyte
percentage by white blood cell count.
For correlation between CD4 count and TLC, we
defined cutoff values as 200 cells/μL and 1200 cells/μL
respectively [8], and compared CD4 count with each
parameter separately. Data was analyzed in SPSS 16. The
correlation coefficient established correlation and kappa
coefficient showed agreement between CD4 count and
these parameters. Sensitivity, specificity and positive and
negative predictive values for using direction on TLC
changes as a marker for direction of CD4 changes were
calculated. P< 0.05 was considered as statistically signifi-
cant for all tests.
This study was approved by the ethical committee of
Department of Medical Microbiology, Immunology andParasitology, College of Medicine and Health Sciences,
University of Gondar Oral and verbal informed consent
was obtained from the patients prior to enrolment. After
obtaining consent, demographic questionnaires were
completed and blood was drawn for CD4 cell count and
CBC.
Results
Total of 400 ART naive HIV infected subjects were
included in this study, among which 278 (69.5%) were
females. The mean (standard deviation) age was 33.7 (9.2)
years (ranging from 18–70 years). The mean and SD of
CD4 count and TLC are shown in Table 1. Comparing
with both sexes CD4 count of female patients was higher
than male patients. However, there existed no statistical
difference in both sexes. Moreover no difference was
found between both sexes concerning age and TLC
(Table 2). There was positive correlation between CD4
and TLC (r= 0.333, P = 0.001). Among 292 patients, 245
cases had TLC >1200 cells/μL and CD4> 200 cells/μL,
while 47 patients had TLC≤ 1200 cells/μL and CD4≤ 200
cells/μL. In lingering 108 patients, there were no positive
correlations between TLC and CD4 count, of whom 96
patients had TLC> 1200 cells/μL, but CD4< 200 cells/μL
and 12 Patients had TLC< 1200 cells/μL, but CD4> 200
cells/μL. Sensitivity, specificity, PPV, and NPV for TLC
cutoff values as compared to CD4 count of <200 cells/
mm3 are listed in Table 3. A TLC of ≤1200 cells/mm3 was
found to have sensitivity (32.86%), specificity (95.33%),
PPV (79.7%), and NPV (71.9%) for predicting a CD4 count
of <200 cells/mm3. Kappa coefficient for agreement be-
tween CD4 count and TLC was 0.24 fair agreement was
observed between CD4 count and TLC (Table 4).
Discussion
CD4 cell count of ≤ 200 cell/μ L is vital marker in the
management of HIV/AIDS patients; it is at this stage
Table 3 Validity and predictive value between CD4 count and TLC among HIV infected patients in different age
categories at Gondar University Hospital, 2011
Age Marker N P SE SP PPV NPV Kappa P - value
In all age group CD4 count≤ 200 cell/μL 143 35.8 100 100 100 100 0.24 0.001
TLC≤ 1200 cell/μL 59 14.8 32.86 95.33 79.66 71.85
18-29 CD4 count≤ 200 cell/μL 36 9.0 100 100 100 100
TLC≤ 1200 cell/μL 12 3.0 22.22 95.65 66.66 75.86 0.22 0.002
30-39 CD4 count≤ 200 cell/μL 66 16.5 100 100 100 100
TLC≤ 1200 cell/μL 33 8.2 39.39 92.92 78.78 69.69 0.35 0.000
40-49 CD4 count≤ 200 cell/μL 26 6.5 100 100 100 100
TLC≤ 1200 cell/μL 12 3.0 26.92 90.74 58.33 72.05 0.20 0.038
50 & above CD4 count≤ 200 cell/μL 16 4.0 100 100 100 100
TLC≤ 1200 cell/μL 7 1.8 43.75 100 100 55 0.38 0.011
Abbreviation: N, number; P, Prevalence (%); SE, Sensitivity (%); SP, Specificity (%); PPV, Positive predictive value; NPV, Negative predictive value; CD4, T-lymphocyte
CD4 positive; TLC, Total lymphocyte count; HIV, Human Immunodeficiency virus.
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trimoxazole prophylaxis is required [9]. Although CD4
cell count is considered the best laboratory marker of
HIV infection, it is an expensive test and not widely
available because of lack of sophisticated equipment.
This problem is more in resource-constrained develop-
ing countries where the majority of people infected with
HIV are living. To overcome this problem, WHO has
recommended that irrespective of the CD4 cell count,
ART can be started on patients who have WHO stage III
or IV disease and on patients who have WHO stage II
disease with TLC of ≤1200/μ L (which can substitute
CD4 cell count of ≤200/μ L), especially in resource-
constrained areas [10].
Results of this study demonstrated that there is a posi-
tive correlation between CD4 count and TLC. This was
in agreement with study conducted by Seyed et al. [11].
The present study showed that in three fourths of
patients, TLC is a suitable predictor of CD4 count. This
finding is consistent with other reports [12,13]. In this
study, we found that 24% of patients had TLC> 1200
cells/μL in spite of CD4< 200 cells/μL that is lower than
38% but higher than 18% reported in Nigeria [14] and
Iran [11] respectively.
Several studies revealed reasonably adequate sensitivity
and specificity to consider TLC as a surrogate measure for
CD4 [5,6]. However, this study Supported by the notions
of Deresse and Eskindir [15], as we observed lowTable 4 Agreement between CD4 count and TLC among
HIV infected patients at Gondar University Hospital, 2011
Parameters CD4 count(cell/μL) Kappa Approx. Sig
≤200 >200 0.24 0.001
TLC >1200 cell/μL 47 12
≤1200 cell/μL 96 245
Abbreviation: CD4, T-lymphocyte CD4 positive; TLC, Total lymphocyte count;
Kappa coefficient for agreement; value< 0.05, significant.sensitivity and specificity of TLC as an alternate marker to
initiate ART. In our study, the sensitivity and specificity of
TLC< 1200 to predict CD4 count< 200 were 32.86% and
95.33%, respectively and these figures were lower than
what is reported recently from India, 59% and 94%,
respectively [7]. As it was reported by Jacobson and collea-
gues [6], TLC may still be used in resource limited area
with the understanding of its low sensitivity and specifi-
city. Stebbing and colleagues also indicated that despite
minimally less reliability of TLC as a surrogate for CD4,
TLC is important tool in the absence of expensive equip-
ment to measure CD4 [16]. In conclusion, this study
showed that low sensitivity and specificity of TLC as a sur-
rogate measure for CD4 count. Moreover, CD4 cell counts
of< 200 cells/mm3 were found in 96 cases (24%) with
TLCs of ≤1200 cells/mm3. Thus, 1 in 4 individuals would
have been deprived of needed treatment. Therefore, we
recommend keep on expansion of access to CD4 counter.
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